Login
$ELDN
$2.01 +$0.04 (2.23%) After hours

$ELDN 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026

13 Aug 2026 8-K: Results of Operations and Financial Condition

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026

22 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Eledon Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as ...

13 May 2026 8-K: Results of Operations and Financial Condition

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study

19 Mar 2026 8-K: Results of Operations and Financial Condition

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study

02 Jan 2026 8-K: Unregistered Sales of Equity Securities

Warrant Shares: ________ Issue Date: ________, 20__Initial Exercise Date: ________, 20__

14 Nov 2025 8-K: Results of Operations and Financial Condition

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus

13 Nov 2025 8-K: Entry into a Material Definitive Agreement

Pre-Funded Warrants to Purchase up to 15,151,515 Shares of Common Stock

07 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

14 Aug 2025 8-K: Results of Operations and Financial Condition; Non-Reliance on Previously Issued Financial Statements

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart

06 Aug 2025 8-K: Regulation FD Disclosure

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

12 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Eledon Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as ...

14 May 2025 8-K: Results of Operations and Financial Condition

On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025

07 Apr 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the comments made regarding us in Item 4.01 of Form 8-K of Eledon Pharmaceuticals, Inc. dated April, 7, 2025 and are in agreement with those statements.

20 Mar 2025 8-K: Results of Operations and Financial Condition

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital

20 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation

On December 16, 2024, Eledon Pharmaceuticals, Inc. (the “Company”) entered into a letter agreement with David-Alexandre Gros, its CEO (the “Agreement”), amending his employment agreement dated September 9, 2020 and first amended April 27...

12 Nov 2024 8-K: Results of Operations and Financial Condition

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025

30 Oct 2024 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Pre-Funded Warrants to Purchase up to 4,931,507 Shares of Common Stock

29 Oct 2024 8-K: Regulation FD Disclosure

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

01 Oct 2024 8-K: Unregistered Sales of Equity Securities

On September 30, 2024 and October 1, 2024, Eledon Pharmaceuticals, Inc. (the “Company”) completed the sale of 1,527,400 and 200,000 shares, respectively, of its common stock, $0.001 par value per share, pursuant to a third closing contem...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support